ZIM Laboratories Ltd
As of 20 Nov 2026, ZIM Laboratories is in Stage 2, the uptrend phase, now in week 27 (since 13 May 2026). It closed at ₹148, 3.2% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. More about the company
Pro read
ProZIMLAB is about 6 months into its Stage 2 advance, 7% above its 50-day average and 3% under its 52-week high. Moves this far along have tended to keep doing well for as long as the trend stays intact.
Its relative strength is 96 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Stocks with a similar setup at this point in their move ran 0.7 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 17% above entry.
The trend read holds while it stays in Stage 2. A close below ₹138, its 50-day average, would put it at rest; ₹122, 20% under its 52-week high of ₹153, is where a trailing stop would sit.
Setup-score rank among Stage 2 peers: #26 of 50 in Pharmaceuticals · #33 of 61 in Health Care
Is ZIMLAB early, or has it already run? Pro answers that for every NSE stock, after every close.
ZIMLAB among Pharmaceuticals11th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …11 | ZIMLAB | Stage 2 · wk 27 | 96 | +11.7% |
Mutual fund holdings
Held by 1 mutual funds in portfolios to October 2026: 1 active funds and 0 index funds and ETFs.
In October, no active fund changed its holding.
All 1 funds and what each did in October
Mutual funds holding ZIMLAB: the ten largest and the month’s moves →
ZIM Laboratories: quick answers
What stage is ZIM Laboratories in?
As of 20 Nov 2026, ZIM Laboratories (ZIMLAB) is in Stage 2, the uptrend phase. It entered Stage 2 on 13 May 2026 and is in week 27. What the four stages mean
Is ZIM Laboratories in an uptrend?
Yes. ZIM Laboratories is in a Stage 2 uptrend. It trades 38.2% above its 200-day average, which is rising.
How far is ZIM Laboratories from its 52-week high?
ZIM Laboratories closed at ₹148 on 20 Nov 2026, 3.2% below its 52-week high of ₹153. Its 52-week low is ₹60.26.
How has ZIM Laboratories performed over the past year?
As of 20 Nov 2026, ZIM Laboratories is up 101.2% over the past year and up 104.9% so far in 2026.
Which sector and industry is ZIM Laboratories in?
ZIM Laboratories is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.